NCT01354379View on ClinicalTrials.gov

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

PHASE1CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

July 31, 2012

Conditions
Healthy Adult Volunteers
Interventions
BIOLOGICAL

NB-1008

NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.

BIOLOGICAL

Fluzone IN

The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).

Trial Locations (1)

66219

Johnson County Clin-Trials, Lenexa

Sponsors
All Listed Sponsors
lead

NanoBio Corporation

INDUSTRY